Centessa Pharmaceuticals PLC ADR

Yahoo Finance • 27 days ago

LifeSci Capital Reaffirms Buy Rating on Centessa Pharmaceuticals (CNTA) with a $39 PT, Anticipates Key Orexin Pipeline Data

Centessa Pharmaceuticals (NASDAQ:CNTA) is one of the best up and coming stocks with huge upside potential. On September 9, LifeSci Capital analyst Francois Brisebois reiterated a Buy rating on Centessa Pharmaceuticals and set a price targe... Full story

Yahoo Finance • last month

Centessa rated Outperform at Oppenheimer on ORX750 potential

[Wall Street New York stock exchange stock market] alexsl Centessa Pharmaceuticals (NASDAQ:CNTA [https://seekingalpha.com/symbol/CNTA]) has been rated as Outperform at Oppenheimer, reflecting strong conviction in the company's lead asset,... Full story

Yahoo Finance • 2 months ago

Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Second Quarter of 2025

Advancing a broad, potential best-in-class orexin receptor 2 (OX2R) agonist franchise, with key data readouts expected this year ORX750 Phase 2a CRYSTAL-1 study for the treatment of narcolepsy type 1 (NT1), narcolepsy type 2 (NT2) and idi... Full story

Yahoo Finance • 2 months ago

Thermo Fisher Scientific Inc Sees Significant Reduction in Eaton Vance Worldwide Health ...

Insights from the Fund's Second Quarter 2025 N-PORT Filing Eaton Vance Worldwide Health Sciences Fund (Trades, Portfolio) recently submitted its N-PORT filing for the second quarter of 2025, revealing strategic investment decisions made d... Full story

Yahoo Finance • 3 months ago

Centessa Pharma (CNTA) CBO Weinhoff sells $155,598 in shares

Gregory M. Weinhoff, Chief Business Officer of Centessa Pharmaceuticals PLC (NASDAQ:CNTA), a $2.06 billion market cap biotech company, sold 10,000 ordinary shares on July 25, 2025, for $155,598. The shares were sold at prices ranging from... Full story

Yahoo Finance • 3 months ago

Alkermes Offers The Next Proof Point For Its Narcolepsy Approach. Stock Dives.

Alkermes stock skidded Monday on the back of mixed results for its experimental narcolepsy treatment, an orexin agonist. Continue Reading View Comments... Full story

Yahoo Finance • 4 months ago

Centessa Pharma (CNTA) CBO Weinhoff sells $138k in shares

Centessa Pharmaceuticals PLC (NASDAQ:CNTA) Chief Business Officer Gregory M. Weinhoff sold 10,000 ordinary shares of the company on June 25, 2025, for a total of $138,642. The shares were sold at prices ranging from $13.60 to $14.06. On th... Full story

Yahoo Finance • 4 months ago

Centessa Pharmaceuticals' Accardi sells $210,000 in shares

Mario Alberto Accardi, President, Orexin Program at Centessa Pharmaceuticals PLC (NASDAQ:CNTA), sold 15,000 ordinary shares of the company on June 24, 2025, for $14.00 each, totaling $210,000. The transaction comes as the stock has shown s... Full story

Yahoo Finance • 4 months ago

Centessa Pharma CEO Saha sells $694,826 in shares

Centessa Pharmaceuticals PLC (NASDAQ:CNTA), a biotech company with a market capitalization of $1.69 billion, saw its Chief Executive Officer Saurabh Saha sell 55,000 ordinary shares of the company on June 20, 2025, for a total of $694,826.... Full story

Yahoo Finance • 4 months ago

Alkermes upgraded at UBS on prospects for sleep disorder therapy

[Wall Street sign, New York City, USA] mbbirdy/E+ via Getty Images UBS upgraded Alkermes (NASDAQ:ALKS [https://seekingalpha.com/symbol/ALKS]) to Buy from Neutral on Tuesday, citing prospects for Irish biotech’s orexin 2 receptor (OX2R) ag... Full story

Yahoo Finance • 4 months ago

Centessa Pharmaceuticals Announces Clearance of Investigational New Drug Application (IND) for ORX142, a Novel Orexin Receptor 2 (OX2R) Agonist; Clinical Data in Acutely Sleep-Deprived Healthy Volunteers Planned for this Year

BOSTON and LONDON, June 16, 2025 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has cleared the IND to initiate a... Full story

Yahoo Finance • 5 months ago

Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences

BOSTON and LONDON, May 19, 2025 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to discover and develop transformational medicines for patients, today announced that memb... Full story

Yahoo Finance • 5 months ago

Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the First Quarter of 2025

Advancing a broad, potential best-in-class orexin receptor 2 (OX2R) agonist franchise, with key data readouts expected this year ORX750 Phase 2a CRYSTAL-1 study for the treatment of narcolepsy type 1 (NT1), narcolepsy type 2 (NT2) and idi... Full story

Yahoo Finance • 5 months ago

Is Centessa Pharmaceuticals plc (CNTA) the Best Small Cap Stock to Buy with the Biggest Upside Potential?

We recently published a list of Top 11 Small Cap Stocks to Buy with Biggest Upside Potential. In this article, we are going to take a look at where Centessa Pharmaceuticals plc (NASDAQ:CNTA) stands against other top small cap stocks to buy... Full story

Yahoo Finance • 7 months ago

Centessa Pharmaceuticals Reports Business Highlights and Financial Results for the Fourth Quarter and Full-Year 2024

Advancing a broad, potential best-in-class orexin receptor 2 (OX2R) agonist franchise with key data readouts expected in 2025 ORX750 Phase 2a CRYSTAL-1 study for the treatment of narcolepsy type 1 (NT1), narcolepsy type 2 (NT2) and idiopa... Full story

Yahoo Finance • 7 months ago

Centessa Pharmaceuticals Announces Poster Presentation of Phase 1 Clinical Data for ORX750, a novel orexin receptor 2 (OX2R) agonist, at the American Academy of Neurology (AAN) 2025 Annual Meeting

BOSTON and LONDON, March 06, 2025 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to discover and develop medicines that are transformational for patients, today announce... Full story

Yahoo Finance • 2 years ago

Anaptys Expands Immune Cell Modulator Pipeline with Exclusive License to BDCA2 Modulator Antibody Portfolio from Centessa Pharmaceuticals

Anaptys licenses exclusive global development and commercialization rights to a potential best-in-class BDCA2 modulator portfolio IND filing to support clinical development of ANB101 in autoimmune and inflammatory diseases expected in H2 2... Full story

Yahoo Finance • 2 years ago

Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Third Quarter of 2023

SerpinPC: Ongoing registrational PRESent-2 and PRESent-3 studies for the treatment of hemophilia B; New data from ongoing Phase 2a study accepted for poster presentationat American Society of Hematology (ASH) Annual Meeting in December 202... Full story

Yahoo Finance • 2 years ago

Centessa Pharmaceuticals to Present Additional 52-Weeks of Continuous Treatment Data from Third Year of Ongoing Phase 2a Study of SerpinPC for the Treatment of Hemophilia at American Society of Hematology (ASH) Annual Meeting

BOSTON and LONDON, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA) today announced that new data from an additional 52-weeks of continuous treatment from the third year (Part 5) of the ongoing Phase 2a study... Full story

Yahoo Finance • 2 years ago

Centessa Pharmaceuticals Announces Preclinical Data Supporting ORX750’s Potential as a Best-in-Class Oral OX2R Agonist for the Treatment of Narcolepsy and Other Sleep-Wake Disorders

- Preclinical data demonstrated significant activity at low doses of ORX750 in highly predictive translational models of Narcolepsy Type 1 (NT1) - ORX750 advancing in IND-enabling studies; Clinical proof of concept data planned for 2024... Full story